As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

A post-ap­proval com­mit­ment test­ing Imfinzi in a late-stage blad­der can­cer pop­u­la­tion has gone pear-shaped for As­traZeneca, as the check­point in­hibitor failed to help pa­tients live longer in an open-la­bel piv­otal study.

Back in 2017, the PD-L1 drug was grant­ed ac­cel­er­at­ed ap­proval by the FDA for pa­tients with lo­cal­ly ad­vanced or metasta­t­ic blad­der can­cer whose dis­ease has per­sist­ed de­spite plat­inum-con­tain­ing chemother­a­py on the ba­sis of Phase I/II da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER